A RANDOMIZED PROSPECTIVE COMPARATIVE STUDY TO ASSESS THE EFFICACY OF CONCURRENT CHEMORADIATION WITH ERLOTINIB VERSUS CISPLATIN IN LOCALLY ADVANCED HEAD AND NECK CANCER PATIENTS
Main Article Content
Keywords
Abstract
Non-communicable diseases (NCDs) are responsible for the major proportion of mortality worldwide with cancer projected to be the leading cause of death and the single critical barrier to increasing life expectancy globally. (1)
Head and neck cancer (HNC), ranking as the seventh most common cancer globally, encompasses a diverse array of tumours affecting the upper aero digestive tract. Head and neck squamous cell carcinoma (HNSCC) is a group of malignancies originating from the squamous cells lining the tissues of the head and neck region, including the oral cavity, hypo pharynx, nasopharynx, oropharynx, lip, nasal cavity, paranasal sinuses, and salivary glands .
HNSCC is a major global health concern, displaying variable incidence and mortality rates across different geographic areas and demographic characteristics.. (2)
References
1.Epidemiology and survival analysis of head and neck cancer: Results from comprehensive care center in North India. Oral Oncol Rep. 2023 Jun 1;6:100022.
2. Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A. Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Med Sci. 2023 Jun 13;11(2):42.
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209–49.
4. Head and Neck Cancers - NCI [Internet]. 2021 [cited 2024 Feb 19]. Available from: https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet
5. Bagal S, Budukh A, Thakur JS, Dora T, Qayyumi B, Khanna D, et al. Head and neck cancer burden in India: an analysis from published data of 37 population-based cancer registries [Internet]. 2023 [cited 2024 Feb 19]. Available from: http://ecancer.org/en/journal/article/1603-head-and-neck-cancer-burden-in-india-an-analysis-from-published-data-of-37-population-based-cancer-registries
6. Kulkarni MR. Head and Neck Cancer Burden in India. Int J Head Neck Surg. 2013 Apr;4(1):29–35.
7. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet Lond Engl. 2008 May 17;371(9625):1695–709.
8. Chow LQM. Head and Neck Cancer. N Engl J Med [Internet]. 2020 Jan 1 [cited 2024 Feb 20]; Available from: https://www.nejm.org/doi/full/10.1056/NEJMra1715715
9. Head and Neck Cancers | CDC [Internet]. 2023 [cited 2024 Feb 19]. Available from: https://www.cdc.gov/cancer/headneck/index.htm
10. Chauhan R, Trivedi V, Rani R, Singh U. A Study of Head and Neck Cancer Patients with Reference to Tobacco Use, Gender, and Subsite Distribution. South Asian J Cancer. 2022 Feb 2;11(1):46–51.
11. Gold JM, Raja A. Cisplatin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Feb 23]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK547695/
12. Bareschino MA, Schettino C, Troiani T, Martinelli E, Morgillo F, Ciardiello F. Erlotinib in cancer treatment. Ann Oncol. 2007 Jun 1;18:vi35–41.
13. Abdelgalil AA, Al-Kahtani HM, Al-Jenoobi FI. Chapter Four - Erlotinib. In: Brittain HG, editor. Profiles of Drug Substances, Excipients and Related Methodology [Internet]. Academic Press; 2020 [cited 2024 Feb 23]. p. 93–117. (Profiles of Drug Substances, Excipients, and Related Methodology; vol. 45). Available from: https://www.sciencedirect.com/science/article/pii/S1871512519300196
14. Mehta VK. Radiotherapy and Erlotinib Combined: Review of the Preclinical and Clinical Evidence. Front Oncol. 2012 Apr 10;2:31.
15. Carter J, Tadi P. Erlotinib. In: StatPearls [Internet] [Internet]. StatPearls Publishing; 2022 [cited 2024 Feb 24]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554484/
16. Santuray RT, Johnson DE, Grandis JR. New Therapies in Head and Neck Cancer. Trends Cancer. 2018 May 1;4(5):385–96.
17. Tang P, Tsao MS, Moore M. A review of erlotinib and its clinical use. Expert Opin Pharmacother. 2006 Mar 1;7:177–93.
18. Rao K, Kalapurakal S, Chalasani P, Robinson K, Malone J, Clausen C, et al. A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer. Cancer Chemother Pharmacol. 2013 Sep;72(3):545–52.
19. Herchenhorn D, Dias FL, Viegas CMP, Federico MH, Araújo CMM, Small I, et al. Phase I/II Study of Erlotinib Combined With Cisplatin and Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol. 2010 Nov;78(3):696–702.
20. Hayes DN, Raez LE, Sharma AK, Papagikos MA, Yunus F, Parvathaneni U, et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): Preliminary toxicity results. J Clin Oncol. 2010 May 20;28(15_suppl):5580–5580.
21. Kim ES, Kies MS, Glisson BS, Ginsberg LE, Holsinger FC, Burke BJ, et al. Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2006 Jun 20;24(18_suppl):5521–5521.
22. Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, et al. Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial. J Clin Oncol. 2013 Apr 10;31(11):1415–21.
23. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol Off J Am Soc Clin Oncol. 2004 Jan 1;22(1):77–85.
24. Siu LL, Soulieres D, Chen EX, Pond GR, Chin SF, Francis P, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol Off J Am Soc Clin Oncol. 2007 Jun 1;25(16):2178–83.
25. Soulieres D, Chen E, Tsao MS, Klein M, Pond G, Dancey J, et al. 408 A phase II study of erlotinib in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (PHL-002e/NCIC CTG IND.157). Eur J Cancer Suppl. 2004 Sep 1;2:122.
26. Le X, Gleber-Netto FO, Rubin ML, Qing Y, Du R, Kies M, et al. Induction Chemotherapy with or without Erlotinib in Patients with Head and Neck Squamous Cell Carcinoma Amenable for Surgical Resection. Clin Cancer Res. 2022 Jul 1;28(13):2796–806.
27. Cossyleon R, Robinson K, Delfino K, Robbins KT, Rao K. Quality of life following treatment with intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2024 Jan 9;32(2):93.
2. Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A. Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Med Sci. 2023 Jun 13;11(2):42.
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209–49.
4. Head and Neck Cancers - NCI [Internet]. 2021 [cited 2024 Feb 19]. Available from: https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet
5. Bagal S, Budukh A, Thakur JS, Dora T, Qayyumi B, Khanna D, et al. Head and neck cancer burden in India: an analysis from published data of 37 population-based cancer registries [Internet]. 2023 [cited 2024 Feb 19]. Available from: http://ecancer.org/en/journal/article/1603-head-and-neck-cancer-burden-in-india-an-analysis-from-published-data-of-37-population-based-cancer-registries
6. Kulkarni MR. Head and Neck Cancer Burden in India. Int J Head Neck Surg. 2013 Apr;4(1):29–35.
7. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet Lond Engl. 2008 May 17;371(9625):1695–709.
8. Chow LQM. Head and Neck Cancer. N Engl J Med [Internet]. 2020 Jan 1 [cited 2024 Feb 20]; Available from: https://www.nejm.org/doi/full/10.1056/NEJMra1715715
9. Head and Neck Cancers | CDC [Internet]. 2023 [cited 2024 Feb 19]. Available from: https://www.cdc.gov/cancer/headneck/index.htm
10. Chauhan R, Trivedi V, Rani R, Singh U. A Study of Head and Neck Cancer Patients with Reference to Tobacco Use, Gender, and Subsite Distribution. South Asian J Cancer. 2022 Feb 2;11(1):46–51.
11. Gold JM, Raja A. Cisplatin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Feb 23]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK547695/
12. Bareschino MA, Schettino C, Troiani T, Martinelli E, Morgillo F, Ciardiello F. Erlotinib in cancer treatment. Ann Oncol. 2007 Jun 1;18:vi35–41.
13. Abdelgalil AA, Al-Kahtani HM, Al-Jenoobi FI. Chapter Four - Erlotinib. In: Brittain HG, editor. Profiles of Drug Substances, Excipients and Related Methodology [Internet]. Academic Press; 2020 [cited 2024 Feb 23]. p. 93–117. (Profiles of Drug Substances, Excipients, and Related Methodology; vol. 45). Available from: https://www.sciencedirect.com/science/article/pii/S1871512519300196
14. Mehta VK. Radiotherapy and Erlotinib Combined: Review of the Preclinical and Clinical Evidence. Front Oncol. 2012 Apr 10;2:31.
15. Carter J, Tadi P. Erlotinib. In: StatPearls [Internet] [Internet]. StatPearls Publishing; 2022 [cited 2024 Feb 24]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554484/
16. Santuray RT, Johnson DE, Grandis JR. New Therapies in Head and Neck Cancer. Trends Cancer. 2018 May 1;4(5):385–96.
17. Tang P, Tsao MS, Moore M. A review of erlotinib and its clinical use. Expert Opin Pharmacother. 2006 Mar 1;7:177–93.
18. Rao K, Kalapurakal S, Chalasani P, Robinson K, Malone J, Clausen C, et al. A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer. Cancer Chemother Pharmacol. 2013 Sep;72(3):545–52.
19. Herchenhorn D, Dias FL, Viegas CMP, Federico MH, Araújo CMM, Small I, et al. Phase I/II Study of Erlotinib Combined With Cisplatin and Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol. 2010 Nov;78(3):696–702.
20. Hayes DN, Raez LE, Sharma AK, Papagikos MA, Yunus F, Parvathaneni U, et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): Preliminary toxicity results. J Clin Oncol. 2010 May 20;28(15_suppl):5580–5580.
21. Kim ES, Kies MS, Glisson BS, Ginsberg LE, Holsinger FC, Burke BJ, et al. Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2006 Jun 20;24(18_suppl):5521–5521.
22. Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, et al. Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial. J Clin Oncol. 2013 Apr 10;31(11):1415–21.
23. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol Off J Am Soc Clin Oncol. 2004 Jan 1;22(1):77–85.
24. Siu LL, Soulieres D, Chen EX, Pond GR, Chin SF, Francis P, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol Off J Am Soc Clin Oncol. 2007 Jun 1;25(16):2178–83.
25. Soulieres D, Chen E, Tsao MS, Klein M, Pond G, Dancey J, et al. 408 A phase II study of erlotinib in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (PHL-002e/NCIC CTG IND.157). Eur J Cancer Suppl. 2004 Sep 1;2:122.
26. Le X, Gleber-Netto FO, Rubin ML, Qing Y, Du R, Kies M, et al. Induction Chemotherapy with or without Erlotinib in Patients with Head and Neck Squamous Cell Carcinoma Amenable for Surgical Resection. Clin Cancer Res. 2022 Jul 1;28(13):2796–806.
27. Cossyleon R, Robinson K, Delfino K, Robbins KT, Rao K. Quality of life following treatment with intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2024 Jan 9;32(2):93.
Article Sidebar
Published
Dec 17, 2024
Article Details
How to Cite
Dr Ramesh Arya, Dr Manish Verma, Dr Karuna Abgad, & Dr Aishwarya Sharma. (2024). A RANDOMIZED PROSPECTIVE COMPARATIVE STUDY TO ASSESS THE EFFICACY OF CONCURRENT CHEMORADIATION WITH ERLOTINIB VERSUS CISPLATIN IN LOCALLY ADVANCED HEAD AND NECK CANCER PATIENTS. Journal of Population Therapeutics and Clinical Pharmacology, 31(11), 2272-2297. https://doi.org/10.53555/dw7d9475
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Dr Ramesh Arya
Professor and Head of the Department, Department of Radiation Oncology, Mahatma Gandhi Memorial Medical College, Indore, India.
Dr Manish Verma
Associate Professor, Department of Radiation Oncology, Mahatma Gandhi Memorial Medical College, Indore, India.
Dr Karuna Abgad
Resident Doctor, Department of Radiation Oncology, Mahatma Gandhi Memorial Medical College, Indore, India.
Dr Aishwarya Sharma
Resident Doctor, Department of Radiation Oncology, Mahatma Gandhi Memorial Medical College, Indore, India.
How to Cite
Dr Ramesh Arya, Dr Manish Verma, Dr Karuna Abgad, & Dr Aishwarya Sharma. (2024). A RANDOMIZED PROSPECTIVE COMPARATIVE STUDY TO ASSESS THE EFFICACY OF CONCURRENT CHEMORADIATION WITH ERLOTINIB VERSUS CISPLATIN IN LOCALLY ADVANCED HEAD AND NECK CANCER PATIENTS. Journal of Population Therapeutics and Clinical Pharmacology, 31(11), 2272-2297. https://doi.org/10.53555/dw7d9475